Showing 3161-3170 of 4262 results for "".
- FDA Approves Ortho Dermatologics' Jublia to Treat Onychomycosis in Patients As Young As Six Years Oldhttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-jublia-to-treat-onychomycosis-in-patients-as-young-as-six-years-old/2460371/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics received FDA approval for a supplemental New Drug Application (sNDA) for Jublia (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, which extends the age range incl
- Sun Pharma Survey: Impact of Psoriasis on Patients is Extensivehttps://practicaldermatology.com/news/sun-pharma-survey-impact-of-psoriasis-on-patients-is-extensive/2460284/The impact of moderate-to-severe plaque psoriasis on social and personal interactions can be extensive, results of a new survey from Sun Pharma confirm. In fact, 44 percent of respondents said that they often or sometimes feel humiliated by the appearance of psoriasis. More than a quarter (28 per
- Aerolase and Eucerin Join Forces to Optimize Patient Outcomes in Laser Treatmentshttps://practicaldermatology.com/news/aerolase-and-eucerin-join-forces-to-optimize-patient-outcomes-in-laser-treatments-1/2460277/Aerolase and Eucerin are working together to optimize laser treatment protocols in the D-A-CH-region (Germany-Austria-Switzerland). Furthermore, both companies will develop therapies for adjunctive care post-laser treatments. Both companies will also conduct a joint symposium
- DermWire Exclusive: Meet Allē, Allergan’s Upgraded Patient Loyalty Programhttps://practicaldermatology.com/news/dermwire-exclusive-meet-alle-allergans-upgraded-patient-loyalty-program/2460244/Allergan’s Brilliant Distinctions customer loyalty program is getting a facelift in honor of its 2nd decade. The program is smarter, faster and now goes by Allē. It’s much more than a new name, shares Carrie Strom, Allergan’s Senior Vice President o
- BTL Files Patent Infringement Lawsuit Against Allergan and Zimmer Related to Emsculpthttps://practicaldermatology.com/news/btl-files-patent-infringement-lawsuit-against-allergan-and-zimmer-related-to-emsculpt-1/2460239/BTL Aesthetics' US affiliate has filed a lawsuit against Allergan plc, Ireland and its affiliates, and Zimmer MedizinSysteme GmbH, Germany, and its affiliate, in the US Federal District Court for the District of Delaware. The lawsuit asserts
- Live Zoster Vaccine Safe and Effective for Patients on TNF Blockershttps://practicaldermatology.com/news/live-zoster-vaccine-safe-and-effective-for-patients-on-tnf-blockers/2460213/The live zoster virus vaccine is safe for people who are currently receiving tumor necrosis factor inhibitor (TNFi) biologic therapies for various indications, according to
- Psoriasis Onset Determines if Psoriatic Arthritis Patients Develop Arthritis or Psoriasis Firsthttps://practicaldermatology.com/news/psoriasis-onset-determines-if-psoriatic-arthritis-patients-develop-arthritis-or-psoriasis-first/2460212/Age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis., finds a new study presented at the 2019 ACR/ARP Annual Meeting in Atlanta. Additionally, pustular psoriasis is associated with arthritis onset two years earlier than the in
- AbbVie Launches “Let Me Be Clear” to Urge Psoriasis Patients to Speak Uphttps://practicaldermatology.com/news/abbvie-launches-let-me-be-clear-to-urge-psoriasis-patients-to-speak-up/2460202/AbbVie is launching Let Me Be
- Five-Year Retrospective Study Shows 98.9 Percent Cure Rate for NMSC Patients Treated with Superficial Radiation Therapyhttps://practicaldermatology.com/news/five-year-retrospective-study-shows-989-percent-cure-rate-for-nmsc-patients-treated-with-superficial-radiation-therapy/2460013/Sensus Healthcare, Inc. shared topline results from a five-year retrospective study of non-melanoma ski
- PellePharm: Phase 3 Trials for Patidegib for Gorlin Syndrome Underwayhttps://practicaldermatology.com/news/pellepharm-phase-3-trials-for-patidegib-for-gorlin-syndrome-underway-1/2459990/